A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488

Inclusion Criteria:

• Patients that have completed their last visit ML21530 and MA21488 in core studies and that might benefit from treatment using the study drug according to the investigator's evaluation
• Absence of an adverse event (AE) or current or recent laboratory finding that would prevent the use of the 8 mg/kg dose of the RoActemra/Actemra study drug
• Receiving outpatient treatment
• For women who are not postmenopausal and are not surgically sterile: agreement to use at least one adequate method of contraception

Exclusion Criteria:

• Patients who have prematurely discontinued ML21530 and MA21488 core studies for any reason
• MA21488 study patients who remained untreated with tocilizumab after it's discontinuation according to the treatment-free remission criteria from MA21488 study.
• Immunization with a live/attenuated vaccine since the last administration of the study drug in ML21530 and MA 21488 core studies
• Diagnosis after the last visit in ML21530 study or after the last visit in MA21488 study of a rheumatic autoimmune disease and/or an inflammatory joint disease other than rheumatoid arthritis
• Abnormal laboratory parameters at the baseline
• History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
• Evidences of a concomitant, serious and uncontrolled illness
• Known active condition or a history of recurrent infections by bacteria, viruses, fungi, mycobacteria or other agents
• Evidence of an active malignant disease, malignancies diagnosed in the last 10 years or breast cancer diagnosed in the last 20 years
• History of drugs of abuse since the inclusion in the ML21530 and MA21488 core studies